Skip to main content
Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging 5/2019

24.11.2018 | Original Article

Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer

verfasst von: Anna Yordanova, Paula Linden, Stefan Hauser, Michael Meisenheimer, Stefan Kürpig, Georg Feldmann, Florian C. Gaertner, Markus Essler, Hojjat Ahmadzadehfar

Erschienen in: European Journal of Nuclear Medicine and Molecular Imaging | Ausgabe 5/2019

Einloggen, um Zugang zu erhalten

Abstract

Background

Data are sparse regarding the feasibility of radioligand therapy (RLT) with [177Lu]Lu-PSMA-617 as a retreatment. We aimed to assess the outcome and safety of rechallenge PSMA-RLT in patients with progressive prostatic cancer who previously benefited from this therapy.

Materials and methods

Patients who received rechallenge therapy at our department from January 2015 to March 2018 were assessed. Non-haematological and haematological adverse events were evaluated from laboratory data and clinical reports and were graded according to the Common Terminology Criteria for Adverse Events (CTCAE v. 5.0). Time to prostate-specific-antigen (PSA) progression and the overall survival (OS) rate of the study patients were calculated from the date of the first rechallenge cycle. Furthermore, the OS calculated from the first cycle baseline PSMA-RLT was compared with the survival of patients who received only baseline PSMA-RLT. The response data were determined using [68Ga]Ga-PSMA-PET/CT and measurements of the tumour marker PSA.

Results

Included in this retrospective study were 30 patients who were initially treated with a median of 3 cycles (range 1–5) of PSMA-RLT and were eventually retreated after a median of 6 months (range 2–26). Each patient received a median of 3 (range 1–6) rechallenge cycles. None of the patients experienced a disabling or life-threatening grade 4 adverse event according to the Common Toxicity Criteria (CTC). Grade 3 toxicity occurred in 8 patients (27%). Serious adverse events included leucopoenia (n = 2), neutropoenia (n = 1), anaemia (n = 4), thrombopenia (n = 4) and elevated renal parameters (n = 1). Irreversible adverse events occurred in 21 patients (70%). The permanent adverse events were mild/moderate (CTC grade 1/2) in 19 patients and serious (CTC grade 3) in two patients, respectively. According to PSA measurements, 75–90% of patients showed a benefit (response/stable) from the first 4 rechallenge cycles. The median OS was 12 months calculated from the first rechallenge cycle and 25 months calculated from the first cycle baseline PSMA-RLT. For comparison, the median OS in patients who received only baseline PSMA-RLT was 9 months. The difference according to the logrank test was significant: p value <0.001. Patients with a PSA decrease after the first cycle of rechallenge PSMA-RLT survived a median of 19 months, while patients with a PSA increase survived only 6 months.

Conclusion

Rechallenge prostate-specific membrane antigen (PSMA) therapy has an acceptable safety profile. The majority of the retreated patients benefited from the rechallenge therapy. Patients who showed a biochemical response achieved a longer OS compared to patients who did not respond. The median OS was significantly longer in patients after rechallenge PSMA-RLT than in patients who received only baseline PSMA-RLT.
Literatur
1.
Zurück zum Zitat Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues [eng]. Clin Cancer Res. 1997;3(1):81–5.PubMed Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues [eng]. Clin Cancer Res. 1997;3(1):81–5.PubMed
2.
Zurück zum Zitat Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises [eng]. J Biol Regul Homeost Agents. 2014;28(4):555–63.PubMed Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Cascinu S, et al. Targeting prostate-specific membrane antigen for personalized therapies in prostate cancer: morphologic and molecular backgrounds and future promises [eng]. J Biol Regul Homeost Agents. 2014;28(4):555–63.PubMed
3.
Zurück zum Zitat Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique [eng]. Histopathology. 2007. https://doi.org/10.1111/j.1365-2559.2007.02635.x. Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR, et al. Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using mutiple tumour tissue microarray technique [eng]. Histopathology. 2007. https://​doi.​org/​10.​1111/​j.​1365-2559.​2007.​02635.​x.
8.
Zurück zum Zitat Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer [ENG]. J Nucl Med. 2015. https://doi.org/10.2967/jnumed.114.147413. Benesova M, Schafer M, Bauder-Wust U, Afshar-Oromieh A, Kratochwil C, Mier W, et al. Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer [ENG]. J Nucl Med. 2015. https://​doi.​org/​10.​2967/​jnumed.​114.​147413.
9.
Zurück zum Zitat Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions [eng]. J Nucl Med. 2015. https://doi.org/10.2967/jnumed.115.161299. Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions [eng]. J Nucl Med. 2015. https://​doi.​org/​10.​2967/​jnumed.​115.​161299.
12.
Zurück zum Zitat Ahmadzadehfar H, Aryana K, Pirayesh E, Farzanehfar S, Assadi M, Fallahi B, et al. The Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA. Iranian Journal of Nuclear Medicine. 2018;26(1):2–8. Ahmadzadehfar H, Aryana K, Pirayesh E, Farzanehfar S, Assadi M, Fallahi B, et al. The Iranian Society of Nuclear Medicine practical guideline on radioligand therapy in metastatic castration-resistant prostate cancer using 177Lu-PSMA. Iranian Journal of Nuclear Medicine. 2018;26(1):2–8.
14.
Zurück zum Zitat Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, et al. Lutetium-177-PSMA-Radioligandentherapie: Konsensus im Rahmen der GKV-finanzierten Versorgung zwischen den Hochschulkliniken in Aachen, Bonn, Düsseldorf, Essen und Köln und dem MDK Nordrhein. [Lutetium-177-PSMA radioligand therapy : consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein] [ger]. Urologe A. 2018. https://doi.org/10.1007/s00120-018-0642-2. Ahmadzadehfar H, Albers P, Bockisch A, Boegemann M, Böhme C, Burchert W, et al. Lutetium-177-PSMA-Radioligandentherapie: Konsensus im Rahmen der GKV-finanzierten Versorgung zwischen den Hochschulkliniken in Aachen, Bonn, Düsseldorf, Essen und Köln und dem MDK Nordrhein. [Lutetium-177-PSMA radioligand therapy : consensus within the framework of GKV-funded care between the university hospitals in Aachen, Bonn, Düsseldorf, Essen, and Cologne and the MDK Nordrhein] [ger]. Urologe A. 2018. https://​doi.​org/​10.​1007/​s00120-018-0642-2.
15.
Zurück zum Zitat Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, et al. Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrationsresistenten Prostatakarzinom. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer] [ger]. Nuklearmedizin. 2016;55(3):123–8.CrossRefPubMed Fendler WP, Kratochwil C, Ahmadzadehfar H, Rahbar K, Baum RP, Schmidt M, et al. Therapie mit 177Lu-PSMA-617, Dosimetrie und Nachsorge beim metastasierten kastrationsresistenten Prostatakarzinom. [177Lu-PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer] [ger]. Nuklearmedizin. 2016;55(3):123–8.CrossRefPubMed
16.
Zurück zum Zitat Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment [eng]. Eur J Nucl Med Mol Imaging. 2017. https://doi.org/10.1007/s00259-016-3481-7. Yadav MP, Ballal S, Tripathi M, Damle NA, Sahoo RK, Seth A, et al. 177Lu-DKFZ-PSMA-617 therapy in metastatic castration resistant prostate cancer: safety, efficacy, and quality of life assessment [eng]. Eur J Nucl Med Mol Imaging. 2017. https://​doi.​org/​10.​1007/​s00259-016-3481-7.
17.
Zurück zum Zitat Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis [eng]. J Nucl Med. 2016. https://doi.org/10.2967/jnumed.116.173757. Rahbar K, Schmidt M, Heinzel A, Eppard E, Bode A, Yordanova A, et al. Response and tolerability of a single dose of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer: a multicenter retrospective analysis [eng]. J Nucl Med. 2016. https://​doi.​org/​10.​2967/​jnumed.​116.​173757.
18.
Zurück zum Zitat Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer [eng]. Eur J Nucl Med Mol Imaging. 2018. https://doi.org/10.1007/s00259-017-3877-z. Rahbar K, Bögeman M, Yordanova A, Eveslage M, Schäfers M, Essler M, et al. Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer [eng]. Eur J Nucl Med Mol Imaging. 2018. https://​doi.​org/​10.​1007/​s00259-017-3877-z.
23.
24.
Zurück zum Zitat Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using 177LuLu-PSMA-617 [eng]. Eur J Nucl Med Mol Imaging. 2017. https://doi.org/10.1007/s00259-017-3716-2. Ahmadzadehfar H, Wegen S, Yordanova A, Fimmers R, Kürpig S, Eppard E, et al. Overall survival and response pattern of castration-resistant metastatic prostate cancer to multiple cycles of radioligand therapy using 177LuLu-PSMA-617 [eng]. Eur J Nucl Med Mol Imaging. 2017. https://​doi.​org/​10.​1007/​s00259-017-3716-2.
25.
Zurück zum Zitat Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-Centre study [eng]. EJNMMI Res. 2015. https://doi.org/10.1186/s13550-015-0114-2. Ahmadzadehfar H, Rahbar K, Kürpig S, Bögemann M, Claesener M, Eppard E, et al. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-Centre study [eng]. EJNMMI Res. 2015. https://​doi.​org/​10.​1186/​s13550-015-0114-2.
26.
Zurück zum Zitat Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer [eng]. Oncotarget. 2016. https://doi.org/10.18632/oncotarget.7245. Ahmadzadehfar H, Eppard E, Kürpig S, Fimmers R, Yordanova A, Schlenkhoff CD, et al. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer [eng]. Oncotarget. 2016. https://​doi.​org/​10.​18632/​oncotarget.​7245.
27.
Zurück zum Zitat Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, et al. The impact of repeated cycles of radioligand therapy using 177LuLu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer [eng]. Eur J Nucl Med Mol Imaging. 2017. https://doi.org/10.1007/s00259-017-3681-9. Yordanova A, Becker A, Eppard E, Kürpig S, Fisang C, Feldmann G, et al. The impact of repeated cycles of radioligand therapy using 177LuLu-PSMA-617 on renal function in patients with hormone refractory metastatic prostate cancer [eng]. Eur J Nucl Med Mol Imaging. 2017. https://​doi.​org/​10.​1007/​s00259-017-3681-9.
28.
Zurück zum Zitat Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving 177LuLu-PSMA-617 radioligand therapy [eng]. Oncotarget. 2017. https://doi.org/10.18632/oncotarget.21600. Ahmadzadehfar H, Schlolaut S, Fimmers R, Yordanova A, Hirzebruch S, Schlenkhoff C, et al. Predictors of overall survival in metastatic castration-resistant prostate cancer patients receiving 177LuLu-PSMA-617 radioligand therapy [eng]. Oncotarget. 2017. https://​doi.​org/​10.​18632/​oncotarget.​21600.
29.
Zurück zum Zitat Bräuer A, Grubert LS, Roll W, Schrader AJ, Schäfers M, Bögemann M, et al. 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer [eng]. Eur J Nucl Med Mol Imaging. 2017. https://doi.org/10.1007/s00259-017-3751-z. Bräuer A, Grubert LS, Roll W, Schrader AJ, Schäfers M, Bögemann M, et al. 177Lu-PSMA-617 radioligand therapy and outcome in patients with metastasized castration-resistant prostate cancer [eng]. Eur J Nucl Med Mol Imaging. 2017. https://​doi.​org/​10.​1007/​s00259-017-3751-z.
31.
Zurück zum Zitat Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3 [eng]. J Clin Oncol. 2016. https://doi.org/10.1200/JCO.2015.64.2702. Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the prostate cancer clinical trials working group 3 [eng]. J Clin Oncol. 2016. https://​doi.​org/​10.​1200/​JCO.​2015.​64.​2702.
32.
Zurück zum Zitat Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-Centre, single-arm, phase 2 study. Lancet Oncol. 2018. https://doi.org/10.1016/S1470-2045(18)30198-0. Hofman MS, Violet J, Hicks RJ, Ferdinandus J, Thang SP, Akhurst T, et al. [ 177 Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-Centre, single-arm, phase 2 study. Lancet Oncol. 2018. https://​doi.​org/​10.​1016/​S1470-2045(18)30198-0.
34.
Zurück zum Zitat Taeger P, Hammes J, Hohberg M, Wild M, Schomaecker K, Kobe C, et al. Discrete evaluation of multi-cycle Lu-177-PSMA-617-therapy effects on bone versus lymph node metastases in patients with metastasized castration-resistant prostate cancer (mCRPC). J Nucl Med. 2018;59(supplement 1):523. Taeger P, Hammes J, Hohberg M, Wild M, Schomaecker K, Kobe C, et al. Discrete evaluation of multi-cycle Lu-177-PSMA-617-therapy effects on bone versus lymph node metastases in patients with metastasized castration-resistant prostate cancer (mCRPC). J Nucl Med. 2018;59(supplement 1):523.
Metadaten
Titel
Outcome and safety of rechallenge [177Lu]Lu-PSMA-617 in patients with metastatic prostate cancer
verfasst von
Anna Yordanova
Paula Linden
Stefan Hauser
Michael Meisenheimer
Stefan Kürpig
Georg Feldmann
Florian C. Gaertner
Markus Essler
Hojjat Ahmadzadehfar
Publikationsdatum
24.11.2018
Verlag
Springer Berlin Heidelberg
Erschienen in
European Journal of Nuclear Medicine and Molecular Imaging / Ausgabe 5/2019
Print ISSN: 1619-7070
Elektronische ISSN: 1619-7089
DOI
https://doi.org/10.1007/s00259-018-4222-x

Weitere Artikel der Ausgabe 5/2019

European Journal of Nuclear Medicine and Molecular Imaging 5/2019 Zur Ausgabe